Enlivex Therapeutics Ltd. ã¯èšåºæ®µéã®å
ç«çæ³äŒç€ŸãšããŠéå¶ãããŠããŸããå瀟ã¯ããã¯ããã¡ãŒãžãæåžžæ§ç¶æ
ã«åããã°ã©ã ããããã«èšèšãããæ¢è£œã®çްèçæ³ã§ãã Allocetra ãéçºããŠããŸããéæåžžæ§ãã¯ããã¡ãŒãžãæåžžæ§ç¶æ
ã«ãªã»ããããããšã¯ãå
ç«ã·ã¹ãã ã®åãã©ã³ã¹åãšçåœãè
ããç¶æ
ã®è§£æ±ºã«äžå¯æ¬ ã§ããåºåœ¢ãããæè¡çãCOVID-19 ãªã©ã®çŸæ£ã¯ããã¯ããã¡ãŒãžãæåžžæ§ç¶æ
ããåããã°ã©ã ããŸããå瀟㮠Allocetra ã¯ãåç¬çæ³ãšããŠããŸãã¯æ²»çè¬ãšçµã¿åãããŠãæºããããŠããªãå»çããŒãºãšããŠå®çŸ©ãããçåœãè
ããèšåºé©å¿çã«å¯Ÿããæ°ããå
ç«çæ³ã®äœçšæ©åºãæäŸã§ããå¯èœæ§ããããŸããå瀟ã¯ãåºåœ¢è
«çã«ããããã§ãã¯ãã€ã³ãé»å®³å€ã®æŽ»æ§ãé«ãã Allocetra ã®è©äŸ¡ã«ã€ããŠãã€ã§ãŒã«ããã»ã³ã¿ãŒãšå
±åç ç©¶ãè¡ã£ãŠããŸããEnlivex Therapeutics Ltd. 㯠2005 幎ã«èšç«ãããã€ã¹ã©ãšã«ã®ãã¹ã·ãªãã«æ¬ç€Ÿã眮ããŠããŸãã